Trade Summary

5 days ago, Apuli Maricel, serving as Chief Accounting Officer at BridgeBio Pharma, Inc. (BBIO), sold 2,000 shares at $80.06 per share, for a total transaction value of $160,120.00. Following this transaction, Apuli Maricel now holds 127,401 shares of BBIO.

This sale represents a 1.55% decrease in Apuli Maricel's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, July 30, 2026 and publicly disclosed via SEC Form 4 filing on Monday, August 3, 2026 at 4:20 PM ET, 4 days after the trade was made.

BridgeBio Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.